

LINCOLN PHARMACEUTICALS LIMITED
 "LINCOLN HOUSE", B/H, SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380060

UN-AUDITED FINANCIAL RESULTS (PROVISIONAL)
 FOR THE QUARTER ENDED ON 31.12.2011

PARTICULARS	CONSOLIDATED						STANDALONE					
	QUARTER ENDED 31.12.2011 (Un-Audited)	QUARTER ENDED 30.09.2011 (Un-Audited)	QUARTER ENDED 31.12.2010 (Un-Audited)	QUARTER ENDED 31.12.2011 (Un-Audited)	QUARTER ENDED 31.12.2010 (Un-Audited)	QUARTER ENDED 31.03.2011 (Un-Audited)	QUARTER ENDED 31.12.2011 (Un-Audited)	QUARTER ENDED 30.09.2011 (Un-Audited)	QUARTER ENDED 31.12.2010 (Un-Audited)	QUARTER ENDED 31.12.2011 (Un-Audited)	QUARTER ENDED 31.12.2010 (Un-Audited)	QUARTER ENDED 31.03.2011 (Un-Audited)
Sales	5187.17	4825.64	4409.45	13867.35	12241.28	18328.57	5081.02	4613.47	4061.60	13394.62	11765.94	17270.03
Other Income	1.67	96.48	58.83	167.62	157.05	203.20	1.66	96.48	58.83	157.64	157.05	203.20
Total Expenditure :												
(a) (Increase)/decrease in stock	-263.32	-255.29	(344.99)	-554.08	-343.40	(135.28)	-263.32	-255.29	(344.99)	-449.44	-343.40	(30.64)
(b) Consumption of Raw-Materials	3420.37	2871.73	3285.68	8594.37	7300.04	12164.72	3308.25	2657.97	2954.38	8256.58	6959.47	11000.22
(c) Staff Cost	366.76	366.76	366.10	1152.96	1028.23	1445.28	394.07	386.76	356.10	1152.96	1028.23	1444.68
(d) Other Expenditure	821.77	710.72	938.83	2416.81	2538.85	3798.83	828.05	706.01	829.79	2398.43	2523.54	3772.07
Gross Profit before Tax, Interest and Depreciation	289.31	697.62	232.66	1316.75	1087.81	1308.22	288.99	224.55	224.55	1294.85	1068.35	1286.90
Interest	172.06	233.80	138.07	499.06	318.00	317.99	172.05	233.67	137.99	497.80	317.25	317.17
Profit before Depreciation & Tax	117.25	463.82	94.59	817.69	769.81	990.23	116.94	470.25	86.56	797.05	751.10	969.73
Depreciation	44.84	40.08	36.57	127.30	105.93	166.68	44.84	40.08	36.57	127.30	105.93	166.68
Profit before Tax	72.41	423.74	58.02	690.39	663.88	823.55	72.10	430.17	49.99	669.75	645.17	803.05
Provision for Taxation	14.55	212.30	(19.72)	208.45	154.21	238.57	21.47	214.48	(28.93)	208.45	148.00	231.57
Profit after Tax	57.86	211.44	77.74	481.94	509.67	584.98	50.63	215.69	75.92	461.30	497.17	571.48
Extra Ordinary Item (Prior period expenses)	5.92	40.65	—	46.57	—	168.34	5.92	40.65	—	46.57	—	168.34
Net Profit after Extra ordinary Items	51.94	170.79	77.74	435.37	509.67	416.64	44.71	175.04	75.92	414.73	497.17	403.14
Equity shares Capital	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08
Reserves and Surplus	—	—	—	—	—	—	—	—	—	—	—	—
(Excluding Revaluation Reserve)	—	—	—	—	—	—	—	—	—	—	—	—
Earning Per Share (EPS) (F.V. Rs.10):-												
a) Basic and diluted EPS before Extraordinary Items (Not Annualised)	0.35	1.30	0.50	2.95	3.12	4.22	0.31	1.32	0.47	2.83	3.91	4.14
b) Basic and diluted EPS after Extraordinary Items (Not Annualised)	0.32	1.05	0.50	2.67	3.12	3.00	0.27	1.07	0.47	2.54	3.91	2.92
Public Shareholding:												
-Number of shares	11589374	12308100	12308100	11589374	12308100	12308100	11589374	12308100	12308100	11589374	12308100	12308100
-Percentage of Shareholding	71.05	75.46	75.46	71.05	75.46	75.46	71.05	75.46	75.46	71.05	75.46	75.46
Promoters and Promoter group Shareholding:												
a) Pledged/Encumbered:												
-Number of shares	NIL	NIL	699400	NIL	699400	699400	NIL	NIL	699400	NIL	699400	699400
-Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	17.47	NIL	17.47	17.47	NIL	NIL	17.47	NIL	17.47	17.47
-Percentage of Shareholding (as a % of the total share capital of the Company)	NIL	NIL	4.29	NIL	4.29	4.29	NIL	NIL	4.29	NIL	4.29	4.29
b) Non-encumbered:												
-Number of shares	4721426	4002700	3303300	4721426	3303300	3303300	4721426	4002700	3303300	4721426	3303300	3303300
-Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	82.53	100.00	82.53	82.53	100.00	100.00	82.53	100.00	82.53	82.53
-Percentage of Shareholding (as a % of the total shares capital of the Company)	28.95	24.54	20.25	28.95	20.25	20.25	28.95	24.54	20.25	28.95	20.25	20.25

NOTES:-

- The above results were reviewed by the audit committee and approved by the Board of Directors at its meeting held on 14.02.2012.
- Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
- Number of complaints for the quarter ended 31.12.2011 - Beginning - Nil, Received - 3, Disposed of-3, and Pending- Nil.
- Figure of the previous period have been regrouped/rearranged/revised (wherever consider necessary) to make them comparable with figure of the current period.
- The Company has one WOS namely Zulfic Healthcare Limited as at 31.12.2011.
- M/s Lincoln Parenteral Ltd. has become subsidiary of the Company w.e.f. 06.12.11. There are no material transaction after it become a subsidiary, hence aforesaid consolidated results do not contain results of said subsidiary company.

Place : Ahmedabad.
 Date : 14.02.2012

For LINCOLN PHARMACEUTICALS LIMITED

(Signature)
 (Hasmukhkhani I. Patel)
 Whole-time Director



(CS: im Lucas)